| Overview |
| bs-9904R-A350 |
| IGFALS Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| ALEXA FLUOR® 350 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human IGFALS/ALS |
| 251-350/605 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3483 |
| Albs; IGFALS; Insulin like growth factor binding protein acid labile subunit; Insulin like growth factor binding protein complex acid labile chain; MGC150140; MGC150141; KIAA4111; mKIAA4111; ALS_HUMAN. |
| The Insulin-like growth factor binding proteins, or IGFBPs, are a family of seven proteins that have co-evolved with the IGFs. IGFBPs serve as shuttle molecules for both IGF-I and IGF-II and confer a level of regulation to the IGF signaling system by influencing the bio-availability, concentration and distribution of IGFs in the extracellular environment. In human circulation, the IGF-binging protein complex requires ALS (IGFBP acid-labile subunit), an extracellular protein involved in receptor-ligand binding and cell adhesion. ALS, detected primarily in plasma, is involved in protein-protein interactions that result in the formation of protein complexes. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz